Abiomed to hold fireside chat at Jefferies Virtual Healthcare Conference.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) • Bio-Rad Laboratories, Inc. Cla…
Abiomed to host virtual clinical data and innovation day.
Publicly traded medical device company Abiomed Inc. has acquired a health technology startup that spun out of the University of Maryland, Baltimore. Abiomed (NASDAQ: ABMD) announced late last week that it has acquired Breethe Inc., a Maryland company that ma…
Valuation metrics in the healthcare sector. Evolution since last month. A list of stocks looking cheap in their industries.
ABMD earnings call for the period ending March 31, 2020.
Investors in Abiomed, Inc. (NASDAQ:ABMD) had a good week, as its shares rose 8.9% to close at US$184 following the...
A University of Maryland, Baltimore-born medical device startup that has been developing a kind of artificial lung was acquired by publicly traded health technology firm Abiomed. Abiomed (NASDAQ: ABMD) announced Thursday its acquisition of Breethe Inc., a Ma…
Abiomed (ABMD) delivered earnings and revenue surprises of 4.17% and -2.61%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Data presented at SCAI 2020 demonstrates Impella reduced in-hospital mortality when placed before a non-emergent PCI is performed.
ABMD earnings call for the period ending March 31, 2020.
Heritage Capital President and CIO Paul Schatz joins Yahoo Finance’s Zack Guzman and Seana Smith to discuss how the coronavirus is impacting the retail industry.
Abiomed (NASDAQ:ABMD) shares have had a really impressive month, gaining 32%, after some slippage. But shareholders...
Shares of Abiomed (NASDAQ: ABMD), a maker of medical devices that improve heart function, soared after the company announced the acquisition of a company that has developed a portable artificial lung and also reported better-than-expected earnings for its fiscal fourth quarter. In addition, the company reported that its implantable heart pump had been successful in helping a pair of critically ill COVID-19 patients survive the disease. Abiomed has acquired Breethe, a private company that has developed a compact extracorporeal membrane oxygenation (ECMO) system -- an artificial lung for patients suffering from cardiogenic shock or respiratory failure.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed’s product portfolio to more comprehe…
Touchstone Sands Capital Institutional Growth Fund recently released its Q1 2020 Investor Letter, a copy of which you can download below. The fund posted a return of -9.45% for the quarter, outperforming its benchmark, the Russell 1000 Growth Index which returned -14.10% in the same quarter. You should check out Touchstone Sands Capital’s top 5 […]
Shares of Abiomed (NASDAQ: ABMD) were soaring 13.8% higher as of 3:26 p.m. EDT on Thursday. The big jump came after the medical device maker announced its fiscal 2020 fourth-quarter and full-year results before the market opened. Abiomed reported Q4 revenue of $206.7 million, down slightly year over year and narrowly missing the consensus Wall Street revenue estimate of $207.2 million.
The medical product companies have partially mitigated the impact of the pandemic driven by the massive adoption of COVID-19 related healthcare-support products and services.
HOLX vs. ABMD: Which Stock Is the Better Value Option?
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to hold fireside chat at Jefferies Virtual Healthcare Conference.
Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.
Monday's top analyst upgrades and downgrades included Amazon.com, American Airlines, American Express, Beyond Meat, Caterpillar, Clorox, eBay, Gilead Sciences, Twitter, Verizon Communications and Wayfair.
Publicly traded medical device company Abiomed Inc. has acquired a health technology startup that spun out of the University of Maryland, Baltimore. Abiomed (NASDAQ: ABMD) announced late last week that it has acquired Breethe Inc., a Maryland company that ma…
Q4 2020 ABIOMED Inc Earnings Call
Abiomed announces Q4 FY 2020 revenue of $207 million and 28.1% operating margin
The company is weathering a coronavirus-related shutdown, and a new purchase will help with diversification.
ABIOMED's (ABMD) flagship Impella saw decline in revenues within United States in Q4.
A University of Maryland, Baltimore-born medical device startup that has been developing a kind of artificial lung was acquired by publicly traded health technology firm Abiomed. Abiomed (NASDAQ: ABMD) announced Thursday its acquisition of Breethe Inc., a Ma…
Publicly traded medical device company Abiomed Inc. has acquired a health technology startup that spun out of the University of Maryland, Baltimore. Abiomed (NASDAQ: ABMD) announced late last week that it has acquired Breethe Inc., a Maryland company that ma…
Abiomed (NASDAQ: ABMD), the first company to implant a totally artificial heart in a patient back in 2001, develops technology to help hearts recover. Abiomed's share price vaulted up 31.8% in April, according to data provided by S&P Global Market Intelligence; most of it came at the end of the month, after the company posted heartening results for the fiscal fourth quarter of 2020. For fiscal year 2020, Abiomed reported total revenue of $840.9 million, up 9% year over year compared to 2019 revenue of $769.4 million.
Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed’s product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation, including patients suffering from cardiogenic shock or respiratory failure such as due to ARDS, H1N1, SARS, or COVID-19. ECMO has also been utilized as a primary method of oxygenation and hemodynamic support for pediatric patients.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces Q4 FY 2020 revenue of $207 million and 28.1% operating margin
A University of Maryland, Baltimore-born medical device startup that has been developing a kind of artificial lung was acquired by publicly traded health technology firm Abiomed. Abiomed (NASDAQ: ABMD) announced Thursday its acquisition of Breethe Inc., a Ma…